Treatment synergy of silicon carbide-coated stenting and abciximab for complex coronary artery lesions: clinical results of a single-center study.
BACKGROUND
The aim of this study was to evaluate the combination of a silicon carbide-coated stent with the periprocedural use of abciximab in patients with type B2/C lesions. The study was a prospective cohort study and was conducted at the University Medical Center of Groningen.


METHODS
Elective percutaneous transluminal coronary angioplasty was performed in a total of 44 patients. All had lesions with type B2/C characteristics and most were relatively small, tortuous and calcified. The involved vessel segment was stented. Silicon carbide-coated stents were used in combination with periprocedural abciximab. The main outcome measures were cardiac death, target vessel revascularization, myocardial infarction, and cerebrovascular accident.


RESULTS
At 6 months of follow-up, only 4 patients had a major adverse cardiac event. Three patients had undergone target vessel revascularization and 1 patient had suffered from a cerebrovascular accident. Sixteen patients underwent re-angiography 6 months after the initial procedure. The average stenosis at 6 months was 15% with a minimal lumen diameter of 2.4 mm.


CONCLUSIONS
A 9% major adverse cardiac event rate and a 7% target vessel revascularization rate at 6 months in type B2/C lesions were recorded. Further investigation on the use of this specific treatment combination is warranted.
van der Vleuten
Pieter A
PA
Department of Cardiology, University Hospital Groningen, Groningen, The Netherlands.
Wijpkema
Jasper S
JS
van den Heuvel
Ad F M
AF
Bosma
Chantal A M
CA
Jessurun
Gillian A J
GA
Tio
René A
RA
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation* / Q000379:methods; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D020099:Coated Materials, Biocompatible; D003131:Combined Modality Therapy; D017023:Coronary Angiography; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017558:Elective Surgical Procedures; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009664:Norway; D011446:Prospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D012828:Silicones / Q000737:chemistry*; D015607:Stents; D015996:Survival Rate; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D020099:Coated Materials, Biocompatible; D007140:Immunoglobulin Fab Fragments; D012828:Silicones; D000077284:Abciximab